- Home
- VNO vs VRNA Comparison
VNO vs VRNA Comparison
Compare VNO & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- VRNA
- Stock Information
- Founded
- VNO 1946
- VRNA 2005
- Country
- VNO United States
- VRNA United Kingdom
- Employees
- VNO N/A
- VRNA N/A
- Industry
- VNO Real Estate Investment Trusts
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- VRNA Health Care
- Exchange
- VNO Nasdaq
- VRNA Nasdaq
- Market Cap
- VNO 7.0B
- VRNA 8.3B
- IPO Year
- VNO N/A
- VRNA 2017
- Fundamental
- Price
- VNO $38.60
- VRNA $104.83
- Analyst Decision
- VNO Hold
- VRNA Buy
- Analyst Count
- VNO 11
- VRNA 11
- Target Price
- VNO $37.91
- VRNA $112.40
- AVG Volume (30 Days)
- VNO 1.9M
- VRNA 5.4M
- Earning Date
- VNO 08-04-2025
- VRNA 08-07-2025
- Dividend Yield
- VNO 1.91%
- VRNA N/A
- EPS Growth
- VNO 248.25
- VRNA N/A
- EPS
- VNO 0.52
- VRNA N/A
- Revenue
- VNO $1,929,890,000.00
- VRNA $118,535,000.00
- Revenue This Year
- VNO N/A
- VRNA $891.79
- Revenue Next Year
- VNO $4.97
- VRNA $78.94
- P/E Ratio
- VNO $73.73
- VRNA N/A
- Revenue Growth
- VNO 2.98
- VRNA N/A
- 52 Week Low
- VNO $26.19
- VRNA $17.96
- 52 Week High
- VNO $46.63
- VRNA $104.99
- Technical
- Relative Strength Index (RSI)
- VNO 50.76
- VRNA 70.87
- Support Level
- VNO $37.45
- VRNA $86.63
- Resistance Level
- VNO $38.88
- VRNA $104.99
- Average True Range (ATR)
- VNO 1.22
- VRNA 2.73
- MACD
- VNO -0.05
- VRNA 0.50
- Stochastic Oscillator
- VNO 59.66
- VRNA 99.24
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.